776
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

, , , , , , , , , , , , , , & show all
Pages 1291-1299 | Received 07 Jul 2015, Accepted 28 Nov 2015, Published online: 14 Jan 2016
Supplemental material

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.8 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.3 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.6 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.7 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.3 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.8 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.7 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.3 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.8 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

ICMJE Form for Disclosure of Potential Conflicts of Interest

Download PDF (1.5 MB)

Supplementary Table 1. Selected treatment-emergent AEs of grade =3 by cycle (N = 103).

Download MS Word (65.9 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.